Skip to content

Study · Animal study (in vivo) · pig · 2021

1 result

Durability of Linear Small-Intestinal Growth Following Treatment Discontinuation of Long-Acting Glucagon-Like Peptide 2 (GLP-2) Analogues.

Hinchliffe T, Pauline ML, Wizzard PR, Nation PN, Brubaker P, Campbell JR, Kim Y, Dimitriadou V, Wales PW, Turner JM

JPEN. Journal of parenteral and enteral nutrition21 Dec 2020Cited by 2 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In neonatal short-bowel piglets, intestinal length further increased after apraglutide cessation at day 14.

    In plain wordsIn piglets with short bowel, intestinal length increased further at day 14 after apraglutide treatment stopped.

    Outcome
    IncreaseIntestinal length after treatment cessation
    Study

    pign: not reported in source

    neonatal short-bowel piglets
    Comparator
    day 7 endpoint
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    5 mg/kg twice weekly · 7 daysAs given in this study (pig).

    Source sentences

    Summary
    Treatment increased intestinal growth in length by day 7 (P = .005), which was maintained (by T) or further increased (by A) at day 14 (P < .001).
    2 context sentences
    Summary · context
    Neonatal short-bowel piglets were assigned to saline control (S), 7-day treatment with teduglutide (T) (0.05 mg/kg twice daily), or 7-day treatment with apraglutide (A) (5 mg/kg twice weekly).
    Summary · context
    Comparisons were made between day 7 and day 14 endpoints using analysis of variance.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.